These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37855991)

  • 21. An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors.
    Wu D; Yan Y; Wei T; Ye Z; Xiao Y; Pan Y; Orme JJ; Wang D; Wang L; Ren S; Huang H
    Cell Rep; 2021 Feb; 34(7):108744. PubMed ID: 33596421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.
    Shieh JM; Wei TT; Tang YA; Huang SM; Wen WL; Chen MY; Cheng HC; Salunke SB; Chen CS; Lin P; Chen CT; Wang YC
    PLoS One; 2012; 7(1):e30240. PubMed ID: 22279574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase
    Shin N; Stubbs M; Koblish H; Yue EW; Soloviev M; Douty B; Wang KH; Wang Q; Gao M; Feldman P; Yang G; Hall L; Hansbury M; O'Connor S; Leffet L; Collins R; Katiyar K; He X; Waeltz P; Collier P; Lu J; Li YL; Li Y; Liu PCC; Burn T; Covington M; Diamond S; Shuey D; Roberts A; Yeleswaram S; Hollis G; Metcalf B; Yao W; Huber R; Combs A; Newton R; Scherle P
    J Pharmacol Exp Ther; 2020 Jul; 374(1):211-222. PubMed ID: 32345620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
    Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
    Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
    Xu S; Sun X; Luo L; Yang Y; Guo Q; Tang S; Jiang Z; Li Y; Han J; Gan W; Yang F; Zhang X; Liu Y; Sun C; He J; Liu M; Zuo D; Zhu W; Wu Y
    Biomed Pharmacother; 2022 Nov; 155():113537. PubMed ID: 36113258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530.
    Locatelli SL; Careddu G; Serio S; Consonni FM; Maeda A; Viswanadha S; Vakkalanka S; Castagna L; Santoro A; Allavena P; Sica A; Carlo-Stella C
    Clin Cancer Res; 2019 Feb; 25(3):1098-1112. PubMed ID: 30352904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.
    Venkannagari S; Fiskus W; Peth K; Atadja P; Hidalgo M; Maitra A; Bhalla KN
    Oncotarget; 2012 Nov; 3(11):1416-27. PubMed ID: 23232026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.
    Jung M; Kim S; Lee JK; Yoon SO; Park HS; Hong SW; Park WS; Kim JE; Kim J; Keam B; Kim HJ; Kang HJ; Kim DW; Jung KC; Kim YT; Heo DS; Kim TM; Jeon YK
    Oncologist; 2019 Aug; 24(8):e740-e748. PubMed ID: 30696721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma.
    Erlich RB; Kherrouche Z; Rickwood D; Endo-Munoz L; Cameron S; Dahler A; Hazar-Rethinam M; de Long LM; Wooley K; Guminski A; Saunders NA
    Br J Cancer; 2012 Jan; 106(1):107-15. PubMed ID: 22116303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma.
    Dong LH; Cheng S; Zheng Z; Wang L; Shen Y; Shen ZX; Chen SJ; Zhao WL
    J Hematol Oncol; 2013 Jul; 6():53. PubMed ID: 23866964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
    Nguyen T; Parker R; Hawkins E; Holkova B; Yazbeck V; Kolluri A; Kmieciak M; Rahmani M; Grant S
    Oncotarget; 2017 May; 8(19):31478-31493. PubMed ID: 28416758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo.
    Huang HL; Peng CY; Lai MJ; Chen CH; Lee HY; Wang JC; Liou JP; Pan SL; Teng CM
    Oncotarget; 2015 Mar; 6(7):4976-91. PubMed ID: 25669976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways.
    Bodo J; Zhao X; Sharma A; Hill BT; Portell CA; Lannutti BJ; Almasan A; Hsi ED
    Br J Haematol; 2013 Oct; 163(1):72-80. PubMed ID: 23889282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vorinostat upregulates MICA via the PI3K/Akt pathway to enhance the ability of natural killer cells to kill tumor cells.
    Xia C; He Z; Cai Y; Liang S
    Eur J Pharmacol; 2020 May; 875():173057. PubMed ID: 32135122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of CUDC-907, a dual phosphoinositide-3 kinase and histone deacetylase inhibitor, in inhibiting proliferation of adult T-cell leukemia.
    Ishikawa C; Mori N
    Eur J Haematol; 2020 Dec; 105(6):763-772. PubMed ID: 32780889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo.
    Beconi M; Aziz O; Matthews K; Moumné L; O'Connell C; Yates D; Clifton S; Pett H; Vann J; Crowley L; Haughan AF; Smith DL; Woodman B; Bates GP; Brookfield F; Bürli RW; McAllister G; Dominguez C; Munoz-Sanjuan I; Beaumont V
    PLoS One; 2012; 7(9):e44498. PubMed ID: 22973455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
    Wallin JJ; Edgar KA; Guan J; Berry M; Prior WW; Lee L; Lesnick JD; Lewis C; Nonomiya J; Pang J; Salphati L; Olivero AG; Sutherlin DP; O'Brien C; Spoerke JM; Patel S; Lensun L; Kassees R; Ross L; Lackner MR; Sampath D; Belvin M; Friedman LS
    Mol Cancer Ther; 2011 Dec; 10(12):2426-36. PubMed ID: 21998291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.
    Liu N; Rowley BR; Bull CO; Schneider C; Haegebarth A; Schatz CA; Fracasso PR; Wilkie DP; Hentemann M; Wilhelm SM; Scott WJ; Mumberg D; Ziegelbauer K
    Mol Cancer Ther; 2013 Nov; 12(11):2319-30. PubMed ID: 24170767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
    Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
    Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.